miR‐138 mediates sorafenib‐induced cell survival and is associated with poor prognosis in cholangiocarcinoma cells

Zheng, Yuejie; Zhang, Jingyu; Ye, Bin

doi:10.1111/1440-1681.13205

Cited by 5 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the prognostic values of SOX4 have previously been reported in some malignant tumors. Some experimental studies have revealed that SXO4 expression is correlated with poor prognosis in patients with tumors, such as CHOL [19] and LAML [20]. The prognostic value of SOX4 was partly validated again in our study, despite some controversial results.…”

Section: Discussionsupporting

confidence: 64%

Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker

Deng,

Wang,

Guo

et al. 2023

Cancers

View full text Add to dashboard Cite

Introduction: SOX4 plays an important role in tumorigenesis and cancer progression. The role of SOX4 in pan-cancer and its underlying molecular mechanism in liver hepatocellular carcinoma (LIHC) are not fully understood. In this study, a comprehensive analysis and experimental validation were performed to explore the function of SOX4 across tumor types. Methods: Raw data in regard to SOX4 expression in malignant tumors were downloaded from the TCGA and GTEx databases. The expression levels, prognostic values, genetic mutation, and DNA promoter methylation of SOX4 across tumor types were explored via systematic bioinformatics analysis. The ceRNA regulatory network, immune characteristics, and prognostic models were analyzed in LIHC. Finally, we conducted in vitro experiments including Western blotting, cell proliferative assay, trypan blue staining, and fluorescence microscopy to further explore the function of SOX4 in LIHC. Results: SOX4 expression was significantly upregulated in 24 tumor types. SOX4 expression level was strongly associated with unfavorable prognoses, genetic mutations, and DNA methylation levels across different tumor types. Especially in LIHC, LINC00152/hsa-miR-139-3p/SOX4 was identified as a crucial ceRNA network. Moreover, this study also provides insight into the roles of SOX4 expression in immune cell infiltration, macrophage polarization, immune subtype, molecular subtype, and immunomodulators, as well as the tumor immune microenvironment (TIME)-related prognosis, in LIHC. The study established six favorable prognostic models to predict LIHC prognosis based on the SOX4-associated genes. Finally, lenvatinib treatment can increase the expression of SOX4 in hepatocellular carcinoma cells and lead to drug resistance. Silencing SOX4 can effectively eliminate the drug resistance caused by lenvatinib treatment and inhibit the proliferation of cancer cells.Conclusions: This study highlights that SOX4 may serve as a promising therapeutic target for tumor treatment.

show abstract

Section: Discussionsupporting

confidence: 64%

Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker

Deng,

Wang,

Guo

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…The analysis of miR-596 expression in real-time qRT-PCR assay was performed as previously described ( 18 , 19 ). Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and real-time qRT-PCR was performed as previously reported ( 18 , 19 ). The primers for miRNAs were synthesized by Sangon Biotech (Shanghai, China).…”

Section: Methodsmentioning

confidence: 99%

“…SOX4 overexpression promotes cell proliferation in rectal cancer, non-small cell lung cancer and breast cancer (15)(16)(17). Recently, studies have indicated that miR-381, miR-138, miR-30a-5p, miR-211 and miR-30a-5p inhibit cell migration and invasion in human GC by down regulating SOX4 (18)(19)(20)(21). In this study, we identified low expression of miR-596 in GC by analyzing three GC miRNA microarray datasets, and serum from GC patients.…”

Section: Introductionmentioning

confidence: 99%

MiR-596 down regulates SOX4 expression and is a potential novel biomarker for gastric cancer

Chen¹,

Gong²,

Dai³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Gastric cancer (GC) is one of the most commonly diagnosed malignancies of the human digestive tract, and currently there is a dearth of effective biomarkers for this disease.Methods: MiR-598 expression levels were analyzed by the cancer genome atlas (TCGA database) mining and verified in GC patient plasma using real-time reverse transcription polymerase chain reaction (RT-PCR) assay. We used the GEPIA and UALCAN databases and immunohistochemistry (IHC) to analyze SOX4 expression. The MTT assay assessed MNK28 and SGC7901 cell proliferation after transfection with miR-596 plasmids. The analytical tools, Functional Enrichment Analysis Tool (FunRich), Database of Immune Cell Expression (DICE) and Tumor IMmune Estimation Resource (TIMER) were used to analyze correlations between SOX4 and immune responses. Furthermore, a Kaplan Meier plotter database explored correlations between miR-596, SOX4 and overall patient survival.Results: Data from TCGA and RT-PCR indicated that miR-598 was lowly expressed in GC patients.The miRWalk database showed that SOX4 was the target genes of miR-596 and also revealed that miR-596 bound directly to SOX4. MiR-596 over-expression further depressed GC cell proliferation. In addition, the FunRich database showed that SOX4 was involved in immune responses, and was further shown to be differentially expressed in CD4+ T cells by DICE. Specifically, TIMER indicated that high expression of SOX4 was negatively correlated with infiltrating CD4+ T cells in stomach adenocarcinoma (STAD).Moreover, high expression of miR-596 and low expression of SOX4 prolonged the overall survival (OS) of GC patients.Conclusions: Our study reveals a crucial role for miR-596 in tumor-associated immune infiltration and predicting prognoses in GC patients.

show abstract

“…On the contrary, miR-138 is a significant contributor to overcoming sorafenib resistance in CCA by modulation of tumor stemness. It targets the transcription factor Sex-determining region Y-related (SRY) high-mobility group box 4 (SOX4), which regulates tumor growth, metastasis, and stemness [ 69 , 72 ]. Downregulation of miR-138 is associated with increased proliferation, migration, and invasion in CCA [ 73 ].…”

Section: Mirna and Drug Resistancementioning

confidence: 99%

Non-coding RNA and Drug resistance in cholangiocarcinoma

Wu,

Jiang,

Chen

2024

Non-coding RNA Research

View full text Add to dashboard Cite

miR‐138 mediates sorafenib‐induced cell survival and is associated with poor prognosis in cholangiocarcinoma cells

Cited by 5 publications

References 30 publications

Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker

Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker

MiR-596 down regulates SOX4 expression and is a potential novel biomarker for gastric cancer

Non-coding RNA and Drug resistance in cholangiocarcinoma

Contact Info

Product

Resources

About